Celldex announces first patient dosed in Phase 2 study of barzolvolimab

Celldex Therapeutics announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis. “Prurigo nodularis is a miserable disease and treatment options are desperately needed that offer early and durable relief by both reducing the relentless itching associated with the disease and allowing for healing of the painful lesions that are the hallmark of PN,” said Diane C. Young, M.D, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. “In our Phase 1b PN study, with just a single dose of barzolvolimab, we demonstrated remarkable clinical results. We are very excited to see what multiple doses of barzolvolimab may offer patients in this important Phase 2 study.”